接触性荨麻疹及相关疾病:临床综述。

IF 4.6 1区 医学 Q2 ALLERGY
Mojca Bizjak, Olivier Aerts, David Pesqué, Melba Muñoz, Riccardo Asero, Margarida Gonçalo, Thomas Rustemeyer, Mitja Košnik, Mark Kačar, An Goossens, Jose Hernán Alfonso, Charlotte G. Mortz, Maryam Ali Al-Nesf, Joachim W. Fluhr, Howard I. Maibach, Ana Maria Giménez-Arnau
{"title":"接触性荨麻疹及相关疾病:临床综述。","authors":"Mojca Bizjak,&nbsp;Olivier Aerts,&nbsp;David Pesqué,&nbsp;Melba Muñoz,&nbsp;Riccardo Asero,&nbsp;Margarida Gonçalo,&nbsp;Thomas Rustemeyer,&nbsp;Mitja Košnik,&nbsp;Mark Kačar,&nbsp;An Goossens,&nbsp;Jose Hernán Alfonso,&nbsp;Charlotte G. Mortz,&nbsp;Maryam Ali Al-Nesf,&nbsp;Joachim W. Fluhr,&nbsp;Howard I. Maibach,&nbsp;Ana Maria Giménez-Arnau","doi":"10.1111/cod.14794","DOIUrl":null,"url":null,"abstract":"<p>Contact urticaria (CoU) is an immediate contact reaction occurring within minutes to an hour after exposure to specific proteins or chemicals. CoU is categorised into non-immunologic (NI-CoU) and immunologic (I-CoU) types, with I-CoU potentially leading to anaphylaxis. Both forms of CoU can be associated with protein contact dermatitis and the CoU syndrome. Patients with I-CoU may also have other type I (immediate) allergic diseases, such as allergic conjunctivitis, rhinitis, asthma or food allergy. This review provides a detailed overview of CoU and related conditions, focusing on triggers, diagnostic methods and management strategies. NI-CoU is typically triggered by low molecular weight chemicals, while I-CoU involves IgE-mediated hypersensitivity to both high molecular weight proteins and low molecular weight chemicals. Early diagnosis is crucial, though CoU is often underrecognized. The diagnostic approach includes a thorough medical history, physical examination, evaluation of photographs, (non)invasive skin tests and in vitro assessments. Management strategies prioritise trigger avoidance and pharmacological treatments when avoidance is not fully possible. For I-CoU, second-generation H<sub>1</sub>-antihistamines are the first-line treatment. Severe cases of I-CoU may benefit from anti-IgE therapy (omalizumab). Patients at risk of anaphylaxis should carry an adrenaline auto-injector and wear a medical alert bracelet.</p>","PeriodicalId":10527,"journal":{"name":"Contact Dermatitis","volume":"93 2","pages":"87-107"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cod.14794","citationCount":"0","resultStr":"{\"title\":\"Contact Urticaria and Related Conditions: Clinical Review\",\"authors\":\"Mojca Bizjak,&nbsp;Olivier Aerts,&nbsp;David Pesqué,&nbsp;Melba Muñoz,&nbsp;Riccardo Asero,&nbsp;Margarida Gonçalo,&nbsp;Thomas Rustemeyer,&nbsp;Mitja Košnik,&nbsp;Mark Kačar,&nbsp;An Goossens,&nbsp;Jose Hernán Alfonso,&nbsp;Charlotte G. Mortz,&nbsp;Maryam Ali Al-Nesf,&nbsp;Joachim W. Fluhr,&nbsp;Howard I. Maibach,&nbsp;Ana Maria Giménez-Arnau\",\"doi\":\"10.1111/cod.14794\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Contact urticaria (CoU) is an immediate contact reaction occurring within minutes to an hour after exposure to specific proteins or chemicals. CoU is categorised into non-immunologic (NI-CoU) and immunologic (I-CoU) types, with I-CoU potentially leading to anaphylaxis. Both forms of CoU can be associated with protein contact dermatitis and the CoU syndrome. Patients with I-CoU may also have other type I (immediate) allergic diseases, such as allergic conjunctivitis, rhinitis, asthma or food allergy. This review provides a detailed overview of CoU and related conditions, focusing on triggers, diagnostic methods and management strategies. NI-CoU is typically triggered by low molecular weight chemicals, while I-CoU involves IgE-mediated hypersensitivity to both high molecular weight proteins and low molecular weight chemicals. Early diagnosis is crucial, though CoU is often underrecognized. The diagnostic approach includes a thorough medical history, physical examination, evaluation of photographs, (non)invasive skin tests and in vitro assessments. Management strategies prioritise trigger avoidance and pharmacological treatments when avoidance is not fully possible. For I-CoU, second-generation H<sub>1</sub>-antihistamines are the first-line treatment. Severe cases of I-CoU may benefit from anti-IgE therapy (omalizumab). Patients at risk of anaphylaxis should carry an adrenaline auto-injector and wear a medical alert bracelet.</p>\",\"PeriodicalId\":10527,\"journal\":{\"name\":\"Contact Dermatitis\",\"volume\":\"93 2\",\"pages\":\"87-107\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cod.14794\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Contact Dermatitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cod.14794\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contact Dermatitis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cod.14794","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

接触性荨麻疹(CoU)是在接触特定蛋白质或化学物质后几分钟至一小时内发生的直接接触性反应。CoU分为非免疫性(NI-CoU)和免疫性(I-CoU)类型,其中I-CoU可能导致过敏反应。两种形式的CoU都可能与蛋白质接触性皮炎和CoU综合征有关。I- cou患者还可能患有其他I型(即时)过敏性疾病,如过敏性结膜炎、鼻炎、哮喘或食物过敏。本文综述了CoU及其相关疾病,重点介绍了病因、诊断方法和治疗策略。NI-CoU通常由低分子量化学物质触发,而I-CoU涉及ige介导的对高分子量蛋白质和低分子量化学物质的超敏反应。早期诊断是至关重要的,尽管常常未被充分认识。诊断方法包括全面的病史、体格检查、照片评价、(非)侵入性皮肤试验和体外评估。管理策略优先考虑触发避免和药物治疗时,避免不完全可能。对于I-CoU,第二代h1抗组胺药是一线治疗。严重的I-CoU病例可能受益于抗ige治疗(omalizumab)。有过敏反应风险的患者应携带肾上腺素自动注射器并佩戴医疗警报手环。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Contact Urticaria and Related Conditions: Clinical Review

Contact urticaria (CoU) is an immediate contact reaction occurring within minutes to an hour after exposure to specific proteins or chemicals. CoU is categorised into non-immunologic (NI-CoU) and immunologic (I-CoU) types, with I-CoU potentially leading to anaphylaxis. Both forms of CoU can be associated with protein contact dermatitis and the CoU syndrome. Patients with I-CoU may also have other type I (immediate) allergic diseases, such as allergic conjunctivitis, rhinitis, asthma or food allergy. This review provides a detailed overview of CoU and related conditions, focusing on triggers, diagnostic methods and management strategies. NI-CoU is typically triggered by low molecular weight chemicals, while I-CoU involves IgE-mediated hypersensitivity to both high molecular weight proteins and low molecular weight chemicals. Early diagnosis is crucial, though CoU is often underrecognized. The diagnostic approach includes a thorough medical history, physical examination, evaluation of photographs, (non)invasive skin tests and in vitro assessments. Management strategies prioritise trigger avoidance and pharmacological treatments when avoidance is not fully possible. For I-CoU, second-generation H1-antihistamines are the first-line treatment. Severe cases of I-CoU may benefit from anti-IgE therapy (omalizumab). Patients at risk of anaphylaxis should carry an adrenaline auto-injector and wear a medical alert bracelet.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Contact Dermatitis
Contact Dermatitis 医学-过敏
CiteScore
4.60
自引率
30.90%
发文量
227
审稿时长
4-8 weeks
期刊介绍: Contact Dermatitis is designed primarily as a journal for clinicians who are interested in various aspects of environmental dermatitis. This includes both allergic and irritant (toxic) types of contact dermatitis, occupational (industrial) dermatitis and consumers" dermatitis from such products as cosmetics and toiletries. The journal aims at promoting and maintaining communication among dermatologists, industrial physicians, allergists and clinical immunologists, as well as chemists and research workers involved in industry and the production of consumer goods. Papers are invited on clinical observations, diagnosis and methods of investigation of patients, therapeutic measures, organisation and legislation relating to the control of occupational and consumers".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信